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Type 1 diabetes (T1D) is characterized by impairment in beta-cell mass and insulin levels,
resulting in hyperglycemia and diabetic complications. Since diagnosis, appropriate
control of glycaemia in T1D requires insulin administration, which can result in side
effects, such as hypoglycemia. In this sense, some bile acids have emerged as new
therapeutic targets to treat T1D and T2D, as well as metabolic diseases. The taurine
conjugated bile acid, tauroursodeoxycholic (TUDCA) reduces the incidence of T1D
development and improves glucose homeostasis in obese and T2D mice. However,
its effects in early-stage of T1D have not been well explored. Therefore, we have
assessed the effects of TUDCA on the glycemic control of mice with early-stage T1D.
To achieve this, C57BL/6 mice received intraperitoneal administration of streptozotocin
(STZ, 40 mg/kg) for 5 days. Once diabetes was confirmed in the STZ mice, they
received TUDCA treatment (300 mg/kg) or phosphate buffered saline (PBS) for 24 days.
After 15 days of treatment, the STZ+TUDCA mice showed a 43% reduction in blood
glucose, compared with the STZ group. This reduction was likely due to an increase in
insulinemia. This increase in insulinemia may be explained, at least in part, by a reduction
in hepatic IDE activity and, consequently, reduction on insulin clearance, as well as an
increase in beta-cell mass and a higher beta-cell number per islet. Also, the groups did
not present any alterations in insulin sensitivity. All together, these effects contributed to
the improvement of glucose metabolism in T1D mice, pointing TUDCA as a potential
therapeutic agent for the glycemic control in early-stage of T1D.
Keywords: type 1 diabetes, insulin, glycemic control, bile acid, TUDCA
Abbreviations: AKT, Protein kinase B; ATF6, Activating transcription factor 6; AUC, Area under the curve; BSA, Bovine
Serum Albumin; CON, Control; DAB, Diaminobenzidine; ER, Endoplasmic Reticulum; IDE, Insulin degrading enzyme;
NOD, Non-obese diabetic; PBS, Phosphate buffered saline; PI3K, Phosphoinositide 3-kinase; RIP-LCMV-GP, Rat insulin
promoter–lymphocytic choriomeningitis virus–glycoprotein; RQ, Respiratory quotient; S1PR2, Sphingosine-1-phosphate
receptor 2; SDS, Sodium dodecyl sulfate; STZ, Streptozotocin; T1D, Type 1 diabetes; TBS, Tris–buffered saline; TUDCA,
Tauroursodeoxycholic acid; UDCA, Ursodeoxycholic acid.
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INTRODUCTION
Type 1 diabetes is an autoimmune disease with progressive
destruction of pancreatic beta-cells (Atkinson et al., 2014;
Maganti et al., 2014) triggered by a genetic predisposition
combined with environmental factors, resulting in a deficiency in
insulin production (Cnop et al., 2005; Daneman, 2006). Besides,
an increase in the insulin clearance also seems to contribute
to the reduction of plasma insulin levels, observed in T1D
rodents (Philippe et al., 1981). Inadequate management of the
disease results in hyperglycemia, which can lead to various
complications, such as neuropathy, retinopathy, nephropathy
(Nathan et al., 2005; Lind et al., 2009), and cardiovascular disease
(Lind et al., 2014). Because insulin plays a pivotal role in glycemic
control, exogenous administration of insulin is required in early
and advanced stages of T1D (Chiang et al., 2014; Henriksson
et al., 2016; Katsarou et al., 2017).
Despite the availability of exogenous insulin, proper control
of blood glucose in T1D patients is difficult to maintain (O’Hara
et al., 2017). Insulin therapy is usually associated with some
side effects, such as hypoglycemia and weight gain (Dewitt and
Hirsch, 2003; Bergenstal et al., 2010), which is aggravated by the
lack of patient compliance with adequate treatment, since the
condition is more common in children and adolescents (Hilliard
et al., 2013; Hynes et al., 2016; O’Hara et al., 2017). Thus,
molecules that could be used for glycemic control, without side
effects or compliance concerns, are a potential treatment for T1D.
In this context, the bile acid TUDCA (Figure 1) has
emerged as a possible candidate for T1D treatment due to its
beneficial effects on glucose homeostasis (Da-Silva et al., 2011).
TUDCA is synthesized in hepatocytes from the conjugation
of UDCA with the amino acid taurine (Hagey et al., 1993).
In the liver, TUDCA stimulates the sphingosine-1-phosphate
receptor 2 (S1PR2), which activates insulin signaling through
the activation of the PI3K/Akt pathway (Studer et al., 2012;
Chiang, 2013). The S1PR2 activation by TUDCA also increases
IDE expression in the liver, improving insulin clearance in
an insulin resistance mice model (Vettorazzi et al., 2017).
In addition, TUDCA acts as a chemical chaperone, reducing
endoplasmic reticulum stress in hepatocytes (Ozcan et al., 2006)
and pancreatic islets (Lee et al., 2010). In the pre-diabetic
FIGURE 1 | Tauroursodeoxycholic Acid (TUDCA) chemical structure.
Molecular Formula: C24H45NO6S.
stage, TUDCA treatment reduces T1D incidence, improving
beta-cell survival and preservation of islet architecture (Engin
et al., 2013). Therefore, the effects of TUDCA on pancreatic
islet and beta-cell mass, as well as its effect on insulin
clearance and IDE modulation in the liver, after T1D induction,
remain unclear. Using this technique, we tested the possible
effects of TUDCA in reverting hyperglycemia in streptozotocin-




Tauroursodeoxycholic acid was purchased from Calbiochem
(São Paulo, Brazil, cat. 580549), and the insulin kit was
acquired from Millipore (Darmstadt, Germany, cat. #EZRMI-
12K). Streptozotocin was purchased from Sigma-Aldrich (St.
Louis, MO, United States, S0130-1G). Western Blot reagents
were purchased from Bio-Rad (Madrid, Spain). IDE antibody
was acquired from Abcam (Cambridge, United Kingdom), and
Tubulin was acquired from Sigma Aldrich (St. Louis, MO,
United States). The insulin antibody was acquired from Dako
North America (Carpinteria, CA, United States, ref. A0564). The
remaining reagents were purchased from Sigma Aldrich.
Animals
All experiments involving animals were approved by the Animal
Care Committee at UNICAMP (License Number: 4747-1). Male,
8-week-old C57Bl/6 mice were obtained from the breeding
colony at UNICAMP and maintained at 22 ± 1◦C on a 12 h
light-dark cycle. As in the Furman (2015) protocol to induce early
stage of type 1 diabetes in the experimental group (STZ n = 21),
an intraperitoneal (i.p.) injection of STZ (40 mg/kg, STZ was
dissolved in 0.5 M citrate buffer, pH 4.5) was administered for
5 days. The same volume of a citrate buffer was injected in the
control group (CON n = 6). Animals with fasting blood glucose
levels above ≥ 200 mg/dL 12 days after the STZ injection were
considered diabetic.
Experimental Protocol
Once diabetes was confirmed in the STZ mice (fast
glycemia > 200 mg/dL), the control group was excluded
from other experiments, and was used only for insulin
tolerance test, measurement of insulin levels and beta-
cell mass in order to validate our early stage T1D model
(Supplementary Figures 5–7). Diabetic mice were randomly
selected and divided into the 2 following groups: (1)
the STZ group (n = 10) received PBS intraperitoneally
(i.p.), and (2) the STZ+TUDCA group (n = 11) received
300 mg/kg TUDCA (dissolved in PBS) i.p. The injections
were administered for 24 days. The fasting glucose and
body weight of both groups were measured on the 7th
and 15th day of the treatment. Mice were killed on the
24th day of treatment in a CO2 chamber and decapitated for
blood collection. The pancreas and liver were removed for
posterior analyses.
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Intraperitoneal Glucose (ipGTT) and
Insulin (ipITT) Tolerance Tests
On the 20th day of TUDCA treatment, the mice were subjected
to 12 h fasting to perform the ipGTT. The fasting blood glucose
level was measured (time 0) by a glucometer. After, the mice
received an i.p. glucose dose of 1 g/kg body weight, and glycemia
was measured at 15, 30, 60, 90, and 120 min. Two days later,
the mice were subjected to 2 h fasting for the ipITT, and the
glycemia was measured before (time 0) and 4, 8, 12, 16, 20, 30,
and 60 min after the i.p. administration of 1 U/kg insulin. The
KITT (glucose disappearance rate) was calculated as previously
described (Akinmokun et al., 1992).
Physiological Measurements
For indirect calorimetry, the mice were allowed 24h for
acclimation to the apparatus 2 days after the ipITT. The mice
remained at rest during a 12 h light/dark cycle. O2 and CO2 were
measured by an Oxylet system (Pan Lab/Harvard Apparatus).
The RQ was calculated from this data.
Plasma Insulin and C-Peptide
Measurements
Mouse insulin and C-peptide Elisa Kits (Darmstadt, Germany,
cat. #EZRMI-13K and #EZRMCP2-21K) were used to measure
plasma insulin and C-peptide. The plasma samples were obtained
by centrifugation of blood samples at 11000 rpm, 15 min, 4◦C.
The assays were performed as indicated by the kit protocol. The
blood samples for insulin and C-peptide measurements were
collected in fed and fasted states at the end of the treatment.
Insulin Degrading Enzyme (IDE) Activity
Liver IDE activity measurement was performed using
the SensoLyte 520 IDE Activity Assay Kit (AnaSpec,
Fremont, CA, United States, cat. AS-72231) following
the manufacturer’s instructions. The total IDE activity
was calculated as previously described (Kurauti et al.,
2016) and normalized per µg of total protein, which
was determined using Bradford reagent. The kinetic
concentration of 5-FAM was also normalized per µg
of total protein.
Western Blot Analysis
Liver samples were collected and homogenized. After
centrifugation at 12000 rpm for 30 min, 4◦C, the protein
was determined using Bradford reagent. For SDS (sodium
dodecyl sulfate) polyacrylamide gel electrophoresis, all
samples were treated with a Laemmli buffer containing
dithiothreitol. After heating to 100◦C for 5 min, proteins
were separated by electrophoresis in a 10% polyacrylamide
gel. The transfer to nitrocellulose membranes was performed
in a Trans Blot transfer for 2 h in 100 V, with a tris/glycine
buffer. After, the membranes were blocked with 5% BSA
for 1 h and were then incubated with polyclonal antibodies
against IDE (Abcam, cat. Ab32216). Tubulin (Sigma Aldrich,
cat. 6074) was used as a control. Visualization of specific
protein bands was performed by incubating the membranes
with appropriate secondary antibodies. Protein bands were
visualized using the Amersham Imager 600 (GE Healthcare
Life Sciences, Buckinghamshire, United Kingdom), which
detected chemiluminescence. The band intensities were
quantified with ImageJ software (National Institutes of Health,
Bethesda, MD, United States). Full scans of the entire original
nitrocellulose membranes are available on Supplementary
information (Supplementary Figures 1–4).
Pancreas Morphometry and
Immunohistochemistry
Pancreas samples from four animals from each group were fixed
in 10% formalin, embedded in Paraplast (Sigma Aldrich, St.
Louis, MO, United States), sectioned into slices of 5 µm and
adhered to individual silanized glasses. The first and the 50th
sections were immunoperoxidase-stained for insulin to quantify
the distribution of pancreatic beta-cells. After the removal of
the Paraplast, the sections were rehydrated and washed with 0.5
M Tris–buffered saline (TBS, pH 7.4) and treated with 0.1 M
sodium citrate buffer (pH 6.0) at 100◦C for antigen retrieval.
The sections were washed again with TBS and blocked against
endogenous peroxidase activity with 3% H2O2. Sections were
washed with TBS and then incubated for 1 h with TBS and
3% BSA followed by primary antibody incubation overnight
at 4◦C. The antibody used was polyclonal guinea pig anti-
insulin (Dako North America, Carpinteria, CA, United States,
ref. A0564) diluted at 1:90 in TBS with 3% BSA. Subsequently,
sections were incubated in the presence of a secondary antibody
for 1 h. The antibody used was anti-guinea pig IgG, diluted
at 1:200. The positive insulin cells were detected with DAB
solution (0.1% DAB and 0.02% H2O2 in TBS). Finally, the
sections were rapidly stained with Harris’ hematoxylin and
mounted for microscopic observation. All islets present in the
sections were covered systematically by capturing images with
a digital camera coupled to a microscope (Olympus DP71;
Olympus BX60, Japan). Pancreatic islets and beta-cells were
measured using ImageJ software (National Institutes of Health,
Bethesda, MD, United States). The pancreas weight was obtained
immediately after the euthanasia. After immunohistochemistry,
the measurement of the circumference of each islet was
denominated as the total area of the islet. Islet/pancreas section
ratio was presented as the total amount of islets in each
section analyzed. The islet and beta-cell mass were calculated by
multiplying the total islet area and beta-cell area by the pancreas
weight (mg) (Lubaczeuski et al., 2015), and the beta cell/islet ratio
was obtained by the total beta-cell area divided by the respective
islet area.
Statistical Analysis
The data are presented as the means ± standard errors mean
(SEM) for 4–21 mice. To evaluate data normality, we applied
the Shapiro-Wilk test. When normal, we used the parametric
Student’s t-test; otherwise, the non-parametric Mann-Whitney
test was adopted. The difference between groups was considered
statistically significant if P ≤ 0.05.
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RESULTS
Streptozotocin Induced Type 1 Diabetes
First, we characterized the early-stage T1D mice using fasting
glucose measurement, and, as expected, the STZ mice presented
hyperglycemia compared to the CON group (Figure 2A).
However, no differences in body weight were noticed between
both groups (Figure 2B). Because the experimental model for
T1D worked, the subsequent experiments were done on STZ
mice. Also, the pancreatic beta-cell mass has been addressed
as well as insulin levels to confirm early-stage T1D, with
reduction of beta-cell mass and insulin levels in STZ-treated mice
(Supplementary Figures 6, 7).
TUDCA Improved Fasting Glycemia in
STZ Mice
In the first week of treatment, fasting glycemia (Figure 2C)
and body weight (Figure 2D) in the STZ+TUDCA group were
similar to the STZ group. However, at the end of the second week
of treatment, fasting glycemia in the STZ+TUDCA mice was
FIGURE 2 | TUDCA treatment improves fasting glycemia from early-stage T1D mice. Fasting glycemia of CON (gray bar, n = 6) and STZ (grid bar, n = 21) (A). Body
weight of CON (gray bar, n = 6) and STZ (grid bar, n = 21) (B) at the end of the streptozotocin administration. Fasting glycemia of STZ (white bar, n = 10) and
STZ + 7 days of TUDCA treatment (black bar, n = 11) (C). Body weight of STZ (white bar, n = 10) and STZ + 7 days of TUDCA treatment (black bar, n = 11) (D).
Fasting glycemia of STZ (white bar, n = 10) and STZ + 15 days of TUDCA treatment (black bar, n = 11) (E). Body weight of STZ (white bar, n = 10) and STZ + 15
days of TUDCA treatment (black bar, n = 11) (F). Data are the mean ± SEM. ∗P ≤ 0.05 (Student’s t-test or Mann-Whitney test).
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reduced by approximately 43% (Figure 2E), compared to the STZ
mice. Body weight remained similar in both groups (Figure 2F).
In addition, there was no difference between the groups in
gastrocnemius muscle and perigonadal fat pad weight (Table 1).
TUDCA Improved Glucose Tolerance but
Did Not Alter Insulin Sensitivity in
STZ Mice
To investigate the effects of TUDCA on glucose homeostasis,
we performed intraperitoneal glucose and insulin tolerance
tests (ipGTT and ipITT). After glucose administration,
both groups had a maximal glucose peak at 15–30 min
(Figure 3A). However, the STZ+TUDCA mice presented
an improved glucose tolerance (Figure 3A), as determined
by the lower AUC of blood glucose during ipGTT
(Figure 3B). As expected, there was no difference between
the groups regarding insulin sensitivity, as determined by
the glucose disappearance rate (KITT) (Figure 3C). Finally,
we observed that plasma insulin levels in a fed, but not
fasted, state was significantly higher in the STZ+ TUDCA
group (Figures 3D,E).
TUDCA Reduced Insulin Clearance, and
IDE Activity, but Not IDE Expression, in
the Liver of STZ Mice
Plasma insulin concentration is controlled by insulin secretion
and clearance. In this case, elevated plasma insulin concentration
in the STZ+TUDCA mice in a fed state could be due to a
reduced insulin clearance. Therefore, we investigated the insulin
clearance by the calculation of C-peptide/insulin ratio after a
glucose challenge. As expected, the plasma insulin level was
higher in the STZ+TUDCA, compared to STZ mice (Figure 4A).
However, the plasma C-peptide was not different between
groups (Figure 4B) suggesting a reduction in insulin clearance,
confirmed by the reduction of C-peptide/insulin ratio in the
STZ+TUDCA, compared to STZ mice (Figure 4C). The enzyme
responsible for insulin clearance is IDE and the major site
of insulin degradation is the liver. Thus, we evaluated IDE
expression and activity in this organ. TUDCA treatment did
not alter IDE expression (Figure 4D), however, IDE activity
in the STZ+TUDCA was reduced, compared to STZ mice
(Figures 4E,F), which explained, at least in part, the elevated
plasma insulin concentration in this group.
TABLE 1 | Final characterization of STZ and STZ+TUDCA mice (Student’s t-test
was used for body weight; Mann-Whitney test was adopted for the other
parameters, P ≤ 0.05).
STZ STZ+TUDCA
Body weight (g) 27.35 ± 1.08 27.85 ± 0.69
Perigonadal fat pad weight (g) 0.34 ± 0.03 0.45 ± 0.09
Gastrocnemius muscle weight (g) 0.51 ± 0.03 0.53 ± 0.02
Data are the mean ± SEM (n = 6).
TUDCA Treatment Increased Beta-Cell
Number per Islet and Mass in STZ Mice
We also investigated the effect of TUDCA treatment on beta-
cell and islet morphology. We observed that pancreas weight
(Figure 5A), total islet area (Figure 5B) and islet/pancreas section
ratio (Figure 5C) remained similar in both groups. However,
islet mass (Figure 5D) was reduced by 10% in the STZ+TUDCA
group. On the other hand, beta-cell mass (Figure 5E) and the
beta-cell number per islet (Figure 5F) increased by 144 and
28%, respectively, in the STZ+TUDCA mice compared with the
STZ mice. Representative figures of the histological pancreatic
sections, stained for insulin, are shown in Figure 5G.
TUDCA Improved Metabolic Flexibility in
STZ Mice
Tauroursodeoxycholic acid treatment increased insulinemia and
reduced glycemia in the STZ mice. Thus, we also investigated
whether these results may alter the metabolic flexibility of
these mice by calculating the RQ. The RQ was calculated
by measuring the amount of carbon dioxide (CO2) produced
in comparison to the amount of oxygen (O2) used, and it
is possible to predict which substrate is being oxidized and
used as a fuel. As expected, during the light period, both
groups presented a RQ ∼0.7, indicating a predominant use of
fatty acid, because they were at rest and fasting (Figure 3F).
On the other hand, during the dark period, when they were
more active and fed, the RQ of the STZ group remained
∼0.7, indicating that they maintained a high rate of fatty acid
oxidation; whereas the STZ+TUDCA mice presented an RQ
∼1.0, suggesting that they used predominantly carbohydrate
oxidation (Figure 3F). Therefore, increased plasma insulin
concentration in the STZ+TUDCA group may increase glucose
uptake and oxidation, contributing to the reduced glycemia.
DISCUSSION
Type 1 diabetes is a highly prevalent disease characterized
by hyperglycemia due to pancreatic beta-cell loss induced by
an autoimmune attack (Chiang et al., 2014), and if not well
controlled, it might lead to retinopathy, nerve damage, kidney
and cardiovascular disease, and death (Atkinson et al., 2014;
Katsarou et al., 2017). Daily exogenous insulin administration
is the main therapeutic strategy for T1D and has been applied
over the past decades. However, insulin therapy may induce
important side effects, such as hypoglycemia, weight gain and
cancer (Dewitt and Hirsch, 2003; Bergenstal et al., 2010; Wu
et al., 2015). Thus, there is a search for molecules that could
improve glucose control in T1D and contribute to the reduction
of insulin dosing, and eventually the deleterious secondary effects
mentioned above. In this context, the bile acid TUDCA has
emerged as an important candidate due to its known benefits
for type 2 diabetic patients, improving the insulin sensitivity in
their peripheral tissues (Ozcan et al., 2006; Kars et al., 2010).
In addition, TUDCA increases insulin secretion in isolated
pancreatic islet from healthy mice (Vettorazzi et al., 2016), and
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FIGURE 3 | TUDCA treatment improves glucose tolerance, increases insulinemia in a fed state and improves metabolic flexibility in early-stage T1D mice. Blood
glucose of STZ (white bar, n = 8) and STZ+TUDCA (black bar, n = 8) during ipGTT (A). Area under the curve (AUC) of total blood glucose concentration of STZ (white
bar, n = 8) and STZ+TUDCA (black bar, n = 8) during ipGTT (B). Glucose disappearance rate during ipITT (KITT) of STZ (white bar, n = 4) and STZ+TUDCA (black
bar, n = 6) (C). Plasma insulin of STZ (white bar, n = 8) and STZ+TUDCA (black bar, n = 10) in fasting (D) and fed (E) states. Respiratory coefficient (RQ) (F) was
determined by indirect calorimetry, during a 12-hour light/dark cycle. RQ of STZ (white bar, n = 4) and STZ+TUDCA (black bar, n = 4) during the light period. In
addition, RQ of STZ (white bar with gray background, n = 4) and STZ+TUDCA (black bar with gray background, n = 4) during the dark period. Data are the
mean ± SEM. ∗P ≤ 0.05 (Student’s t-test or Mann-Whitney test).
prevents T1D development in NOD mice, treated with the
compound during the pre-diabetic stage (Engin et al., 2013).
Since a clinical trial with diabetic patients receiving TUDCA
treatment (Goland and colleagues, Columbia University), is
ongoing, we believe that understanding the mechanism of
action of this bile acid upon glycemic control is important.
Taking this into account, we treated early-stage T1D mice with
TUDCA after the induction of the disease by multiple low
doses of streptozotocin. The multiple low doses of streptozotocin
approach causes partial pancreatic islet damage, activating an
inflammatory process that further induces loss of beta-cell
activity, ultimately resulting in a mild insulin deficiency and
hyperglycemia, without insulin resistance which closely matches
the early stage of T1D in humans (Lenzen, 2008; Furman, 2015).
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FIGURE 4 | TUDCA reduces insulin clearance and Insulin Degrading Enzyme (IDE) activity, but not IDE expression, in the liver of STZ mice. Plasma insulin of STZ
(white bar, n = 7) and STZ+TUDCA (black bar, n = 7) in fed state (A). Plasma C-peptide of STZ (white bar, n = 7) and STZ+TUDCA (black bar, n = 7) in fed state (B).
C-peptide/insulin ratio of STZ (white bar, n = 7) and STZ+TUDCA (black bar, n = 7) in fed state (C). Protein expression of IDE in the liver and its representative
immunoblotting images of STZ (white bar, n = 8) and STZ+TUDCA (black bar, n = 8) (D). Kinetic of IDE activity assay (E) and total IDE activity (F) in the liver of STZ
(white bar, n = 4) and STZ+TUDCA (black bar, n = 5) mice. Fluorescent intensity at Ex/Em = 490/520 nm was recorded every 5 min for 60 min. 5-FAM concentration
was calculated using a standard curve and normalized per µg of total protein. Data are the mean ± SEM. ∗P ≤ 0.05 (Student’s t-test or Mann-Whitney test).
In our study, we aimed to verify the efficiency of TUDCA on a
stage without complete loss of beta-cell, characterizing an early
stage of the disease.
Twelve days after the last streptozotocin administration, the
fasting blood glucose was almost 100% higher in the STZ
group compared with the CON group. Also, STZ mice did
not present alterations regarding insulin sensitivity, however,
this result is a limitation of this study due to the low
number of animals per group in this experiment. Moreover, the
STZ-treated mice presented reduced insulinemia and beta-cell
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FIGURE 5 | TUDCA treatment increases beta-cell mass and beta-cell number
per islet in early-stage T1D mice. Pancreas weight (g) (A); total islet area (µm2)
(B); islet/ pancreas section ratio (C); islets mass (mg) (D); beta-cell mass (mg)
(E); beta-cell/islet ratio (F) of STZ (white bar, n = 4) and STZ+TUDCA (black
bar, n = 4) mice. Representative images of pancreas sections stained for
insulin (G). Data are the mean ± SEM. ∗P ≤ 0.05 (Student’s t-test or
Mann-Whitney test).
mass (Supplementary Figures 6, 7), consistent with previous
streptozotocin multiple low doses T1D protocols (Furman, 2015;
McKillop et al., 2016; Tekula et al., 2018; Khurana et al., 2018).
After streptozotocin administration, we divided the mice into
two groups; one received TUDCA (300 mg/kg) daily through
i.p. injections for 24 days. On the 7th day, the glycemia
was not different between the T1D groups. However, after
15 days of treatment, the fasting glycemia of the STZ+TUDCA
group was significantly reduced compared with the STZ mice,
without any changes in the body weight. The efficiency of
TUDCA in reducing glycemia was confirmed by an ipGTT
(Figure 3A), and it is possible that this improvement in
glucose tolerance was due to the higher plasma insulin levels
observed in these mice.
Insulinemia depends on a balance between insulin secretion
and degradation. In healthy subjects, the liver is the main site
for insulin degradation, which occurs through the involvement
of IDE (Duckworth et al., 1998). IDE malfunction has been
identified in obesity and type 2 diabetic models (Karamohamed
et al., 2003; Erdmann et al., 2009). However, the possible role of
hepatic IDE modulation and its impact upon insulin clearance in
early or advanced T1D mice treated with TUDCA has not been
investigated yet.
Here, we measured the IDE protein content in the liver and
did not find differences between the T1D groups. However,
we observed a decrease in the liver IDE activity in the
STZ+TUDCA mice compared to the STZ mice, suggesting
that the lower IDE activity in the TUDCA treated mice
might contribute to reduced insulin degradation, justifying
the higher insulinemia in the STZ+TUDCA mice. Indeed,
reduced hepatic IDE activity, observed in the STZ+TUDCA
mice, may explain the reduction in the insulin clearance in
this group. It is known that insulin clearance is increased
in the streptozotocin diabetic rodent model (Philippe et al.,
1981), and our findings suggest TUDCA treatment as an
important strategy to improve the impaired insulin clearance
in the T1D patients. These results negate previous data
from our group, which showed that TUDCA increased the
insulin clearance by increasing IDE expression. However,
this study was performed in hyperinsulinemic mice fed with
a high fat diet (Vettorazzi et al., 2017), suggesting that
the TUDCA-induced IDE modulation is dependent on the
insulinemic state.
The effects of TUDCA on the liver do not exclude the
possibility of the involvement of pancreatic islets in this context.
Thus, we evaluated the histology of pancreas from early-
stage T1D mice and observed that the STZ+TUDCA mice
presented increased beta-cell mass and beta-cell number per islet,
suggesting that TUDCA may be able to partially recover beta-
cell mass, which, together with the reduction in IDE activity
and insulin clearance, results in an increased insulinemia and,
consequently, improvement of glucose homeostasis in T1D mice.
The reduction in ER stress and inflammation could be the
molecular mechanism by which TUDCA improves pancreatic
islet homeostasis and beta-cell mass in this study. In fact,
previous studies have shown the chaperone function of TUDCA
in pancreatic islets and beta-cells (Lee et al., 2010; Cadavez et al.,
2014). Also, Engin et al. (2013) shown that TUDCA treatment,
during the pre-diabetic stage, reduces T1D incidence in RIP-
LCMV-GP (rat insulin promoter–lymphocytic choriomeningitis
virus–glycoprotein), keeping the pancreatic islet largely intact,
despite the presence of inflammatory cells, and reduces beta-cell
apoptosis by reducing ER stress in an ATF6-dependent pathway.
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Paradoxically, the STZ+TUDCA mice showed reduced islet
mass compared to the STZ mice. We speculate that this feature
might be a result of reduced immune cell infiltration into the
islets, since it was demonstrated that TUDCA prevents insulitis
in NOD mice in the pre-diabetic state (Engin et al., 2013).
Moreover, TUDCA treatment protects human pancreatic islet,
exposed to a combination of pro-inflammatory cytokines (IL-
1β, TNF-α and IFN-γ), reducing apoptosis induced by these
cytokines (Ocaña et al., 2017).
The T1D patients display metabolic inflexibility due to their
incapacity to adjust uptake of macronutrients according to their
metabolic needs (Kelley and Mandarino, 2000). Healthy mice
preferentially oxidize glucose during the dark cycle (fed state) and
fatty acids in the light cycle (fasted state) (Randle, 1986). Here,
we demonstrated that TUDCA treatment was able to improve
the energetic metabolism in T1D mice, probably due to their
insulinemia recovery.
Taken together, we concluded that TUDCA treatment
increased insulinemia in the STZ-induced diabetic mice in an
early stage of the disease through two distinguished mechanisms:
increasing pancreatic beta-cell mass and decreasing IDE activity
in the liver and consequently reducing insulin clearance. Both
alterations contribute to the improvement of glycemic control
and metabolic flexibility in these mice. These findings suggest that
TUDCA treatment is a potential strategy to counteract glucose
homeostasis disturbance in early-stage type 1 diabetic patients.
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